Circulating LTD4 in patients with hepatocellular carcinoma.
Hepatocellular carcinoma (HCC) is a type of inflammation-related cancer that usually follows chronic inflammations. Leukotriene D4 (LTD4) is a potent biologically active arachidonic acid-derived lipid mediator that is intimately involved in inflammations and cancers. Although previous researches found overexpression of LTD4 in several other cancers, the circulating LTD4 level in HCC remains unknown. The aim of this study was to examine concentrations of LTD4 and analyze its roles in HCC. The results showed that remarkably high circulating LTD4 in HCC versus healthy subjects (p < 0.001). The levels of LTD4 were neither associated with parameters expressing tumor burden, such as AFP, nor with inflammation factors AST and γ-GT. In addition, the significant increase of circulating LTD4 levels was obtained in patients with HCC accompanied by chronic hepatitis B (CHB), compared with those patients suffering HCC alone(P < 0.05). Furthermore, although the slightly lower levels of LTD4 were detected in HCC patients with non-metastasis and therapy compared with metastasis and non-therapy, no significant differences were detected. Taken together, the levels of circulating LTD4 are elevated in HCC and it may participate in the pathogenesis of HCC as an inflammatory factor from CHB disease to HCC.
Zhou
Yan
Y
Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, People's Republic of China.
Guo
Dongmei
D
Li
Huiyu
H
Jie
Shenghua
S
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D006528:Carcinoma, Hepatocellular / Q000097:blood* / Q000556:secondary; D016022:Case-Control Studies; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D017998:Leukotriene D4 / Q000097:blood*; D008099:Liver / Q000378:metabolism*; D008113:Liver Neoplasms / Q000097:blood* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D015996:Survival Rate; D055815:Young Adult
D014408:Biomarkers, Tumor; D017998:Leukotriene D4
Blood. 2001 Jun 1;97(11):3433-40
11369634
Science. 2001 Nov 30;294(5548):1871-5
11729303
Eur J Cancer. 2010 Aug;46(12):2178-86
20413301
Liver Int. 2007 Mar;27(2):174-85
17311611
Am J Respir Cell Mol Biol. 1998 Sep;19(3):453-61
9730873
J Biol Chem. 2000 Sep 29;275(39):30531-6
10851239
Gastroenterology. 2000 Oct;119(4):1007-18
11040187
Eur J Biochem. 1992 Oct 1;209(1):281-9
1327771
N Engl J Med. 2007 Nov 1;357(18):1841-54
17978293
J Pharmacol Sci. 2007 Jan;103(1):24-32
17220595
Anticancer Res. 2008 Mar-Apr;28(2A):873-8
18507031
Ugeskr Laeger. 2009 Jan 19;171(4):243-6
19174041
Gastroenterology. 2003 Jan;124(1):57-70
12512030
Science. 1983 May 6;220(4597):568-75
6301011
Hepatology. 2010 Mar;51(3):817-27
20112424
Lancet. 2001 Feb 17;357(9255):539-45
11229684
Ann N Y Acad Sci. 2009 Feb;1155:206-21
19250206
Lab Invest. 2000 Nov;80(11):1617-28
11092522